0R2M.LSE Regeneron Pharmaceuticals, Inc.

Healthcare Biotechnology London Exchange
- USD
Market cap
-
P/E
13.7x
P/B
-
ROE
15.8%
Dividend yield
0.46%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 0R2M.LSE undervalued?

Graham number

The Graham number of Regeneron Pharmaceuticals, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Regeneron Pharmaceuticals, Inc. fundamental analysis

No fundamental analysis for Regeneron Pharmaceuticals, Inc. yet.

Regeneron Pharmaceuticals, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic r…

Full company profile